The pooled OR from 3 studies involving blood samples from 295 patients with CRC and 189 patients with benign mucosal lesions showed that methylated SFRP2 in CRC was significantly higher than in benign mucosal lesions (OR = 13.66, P = 0.024) (Fig. 6). Here, SFRP2 is linked to colorectal carcinoma.